Back to search results
NCT07268599

Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon

Enrolling by Invitation
Not specifiedAges 18–60Observational
Colvard Kandavel Eye Center
~50 participants
Updated 2025-12-08 on ClinicalTrials.gov
What's tested:Acoltremon

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in Ocular Surface Disease Index at 28 days
Measured over Baseline and 28 days

Conditions

Dry Eye Disease (DED)

Explore related trials

Dry Eye Syndrome

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ganesha R Kandavel, MD · PRINCIPAL_INVESTIGATOR · Colvard Kandavel Eye Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 years or older with clinical diagnosis of DED within past 6 months
Use or desire for artificial tears for DED symptoms within past 2 months
OSDI score \>25 and \<50 at Screening
TBUT \<10 seconds
Baseline tCFS score ≥2 and ≤15 (modified NEI)

Exclusion

History of corneal or conjunctival surgery
History of herpes zoster ophthalmicus, herpes simplex virus keratitis, or other viral corneal infection
History of neurotrophic keratitis
Prior significant facial trauma or sinus surgery
Mental or physical condition impairing ability to complete questionnaires
Use of Restasis®, Xiidra®, or Miebo within 30 days
Use of other topical anti-inflammatory medications within 30 days
Use of varenicline nasal spray within 30 days
Use of artificial tears within 2 hours prior to screening or during study period
Glaucoma requiring topical therapy
Contact lens or eyelid scrub use within 7 days
Punctal plugs within 14 days
Oxervate historical use
Amniotic membrane or Serum Tears historical use
History of Sjögren's disease
History of LASIK within 1 year

What this trial measures

  • Change from baseline in Ocular Surface Disease Index at 28 daysBaseline and 28 days

    Change from baseline in specific 1-5 categorical rating scale scoring at 28 days of dry eye symptoms: Blurriness, burning/stinging, eye irritation/discomfort, photophobia/pain, tired eyes/eye fatigue, sandy/gritty/foreign body sensation